Solid Biosciences: A Cash-Rich Gene Therapy Play That’s Becoming More Than Duchenne
Solid Biosciences (SLDB) is trading at roughly $10.42 with a market cap near $1.0B but carries unusually strong balance-sheet metrics for a clinical-stage biotech. Recent regulatory designations, licensing deals around its next-gen AAV capsid, and pipeline diversification beyond Duchenne muscular dystrophy (DMD) create multiple near-term value cata…